^
Association details:
| Biomarker: | PIK3CA E545K |
|---|---|
| Cancer: | Hepatocellular Cancer |
| Drug: | Piqray (alpelisib) (PIK3CA inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Alpelisib combination treatment as novel targeted therapy against hepatocellular carcinoma
Published date:
10/08/2021
Excerpt:
Alpelisib slowed down the growth of c-Met/H1047R and c-Met/E545K HCC but was ineffective in c-Met/sgPten HCC....In human HCC cell lines transfected with PIK3CA(H1047R), alpelisib synergized with the mTOR inhibitor MLN0128 or the CDK4/6 inhibitor palbociclib to suppress HCC cell growth. In c-Met/H1047R mice, alpelisib/MLN0128 or alpelisib/palbociclib combination therapy caused tumor regression.
DOI:
10.1038/s41419-021-04206-5
